期刊文献+

实时荧光聚合酶链反应检测乙型肝炎病毒聚合酶基因变异 被引量:22

Detection of YMDD mutation during lamivudine therapy by real time fluorimetry PCR
原文传递
导出
摘要 目的 建立一种在拉米夫啶治疗过程中的聚合酶酪氨酸 蛋氨酸 天冬氨酸 天冬氨酸(YMDD)基序变异的检测方法。方法 根据寡核苷酸探针与模板结合时 ,不匹配碱基显著影响熔解温度的原理 ,设计合成 2条荧光标记的特异性探针 ,用实时荧光聚合酶链反应 (PCR)方法对 2 97例患者的 35 4份标本进行YMDD变异检测。结果  35 4份标本中 ,检出YMDD变异株 15 6份 ( 44 1% ) ,其中混合株占 34% ( 5 3/15 6 ) ;有 9份血清标本同时进行了DNA序列分析 ,测序结果同本试验检测的结果完全一致 ;同时发现YMDD变异与血清谷丙氨酸转氨酶异常相关 (P <0 0 1)。结论 本研究建立的实时荧光PCR方法简便、快速、灵敏、经济 ,可用于临床拉米夫啶治疗中YMDD变异的检测。 Objective Setting up a method to detect YMDD mutation during lamivudine therapy. Methods Two specific fluorescent probes were designed, on the unpaired base can remarkably affect melting temperature when oligonucleotide probe binding to DNA template. 297 patients (354 sera samples) were detected YMDD mutation by real time fluorimetry PCR. Results 156 YMDD mutation were found in 354 sera samples (44.1%), in which the mixed variant species were 34%(53/156). In the same time, nine sera samples wre sequenced. The results of sequencing were fully corresponded to those of fluorimetry PCR. The statistical analysis showed that YMDD variants were obviously correlated with ALT level(P<0.01). Conclusion The method described here provides a convenient, rapid, accurate and inexpensive way to monitor YMDD mutation during lamivudine therapy.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2003年第1期37-39,共3页 Chinese Journal of Laboratory Medicine
关键词 乙型肝炎病毒 聚合酶 基因变异 聚合酶链反应 Hepatitis B virus Polymerase chain reaction Variation
  • 相关文献

参考文献9

  • 1Stuyver l;Van Geyt V;De Gendt S.Line probe for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy,2000.
  • 2Allen MI;Deslauriers M;Andrews CW.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine[J],1998(6).
  • 3Gauthier J;Bourne EJ;Lutz MN.Quantitative assessment of HBV viremia and emergence of YMDD variants in chronic hepatitis B patients treated with lamivudine,1999.
  • 4Lai CL;Chien RN;Leung NW.A one-year trial of lamivudine for chronic hepatitis B[J],1998.
  • 5Tassopoulos NC;Volpes R;Pastore G.Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B[J],1999(29).
  • 6Leung NW;Lai CL;Chang TT.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy[J],2001.
  • 7Jardi R;Buti M;Rodriguez FF;Cotrina M,Costa X,Pascual C,Esteban R,Guardia J.Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants[J],1999(1-2).
  • 8Allen M;Gauthier J;Deslauriers M.Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine[J],1999.
  • 9Cane PA;Cook P;Ratcliffe D.Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus[J],1999.

共引文献3

同被引文献145

引证文献22

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部